Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Aveo Pharmaceuticals Inc's Business Segments
Aveo Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 30
Regions Reported
-
Aveo Pharmaceuticals Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product Gross0%
- Product99.1%
- Royalty0.9%
- License0%
- Product Sales Discounts and Allowances0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product Gross | $ 36 | - |
| Product | $ 30 | 99.1% |
| Royalty | $ 0 | 0.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
2 more categories available
Sign in to unlock the full Aveo Pharmaceuticals Inc dataset.
Description of Aveo Pharmaceuticals Inc
Aveo Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for oncology. The companys mission is to provide treatments that can significantly improve the lives of patients with cancer.
Segments
1. Oncology Drug Development: Aveo specializes in the development of novel therapeutics targeting various cancers. Their pipeline includes both early and late-stage candidates, focusing on specific molecular targets and pathways that are critical in tumorigenesis and cancer progression.
2. Commercialization: In addition to drug development, Aveo has a commercial aspect that involves bringing their therapies to market once they receive regulatory approval. This includes marketing strategies, sales force deployment, and patient support programs.
3. Collaborative Partnerships: Aveo often collaborates with larger pharmaceutical companies and research institutions to enhance drug development processes, expand clinical trial capabilities, and access broader markets. These partnerships may focus on co-developing therapies or co-promoting products.
Products
1. Tivdak (tisotumab vedotin): This product is a monoclonal antibody-drug conjugate developed for the treatment of certain types of cancer, particularly cervical cancer. It’s designed to target tumor cells specifically, reducing the harmful effects on healthy tissue.
2. AV-203: A monoclonal antibody targeting the epidermal growth factor receptor (EGFR), which is involved in many cancers. AV-203 is still in the development stage and has shown promise in preclinical studies.
3. AV-101: This investigational compound targets a pathway that could influence cancer cell survival and proliferation. It is currently being evaluated in clinical trials for its efficacy and safety in treating various malignancies.
4. Customized Therapies: Aveo is also exploring the avenue of personalized medicine, which involves tailoring treatments based on the genetic makeup of both the patient and the tumor. This segment holds a lot of potential for the future of oncology.
Services
1. Clinical Trials Support: Aveo offers extensive support for clinical trial design, implementation, and management. They conduct phase I, II, and III trials to assess the safety and efficacy of their drug candidates.
2. Patient Assistance Programs: To enhance patient access to their therapies, Aveo provides patient support programs that help with medication access, treatment options, and support throughout the treatment journey.
3. Scientific Research and Development Services: The company often engages in R&D collaborations, providing expertise in drug discovery, development, and regulatory pathways to support innovative oncology therapies.
4. Regulatory Consulting: Aveo navigates the complex regulatory landscape to secure approvals from health authorities like the FDA. They provide consultancy services on submissions and compliance, ensuring that products meet necessary guidelines.
5. Educational Initiatives: Aveo is involved in educating healthcare professionals and patients about cancer treatment options, the importance of clinical trials, and the potential benefits of their therapies.
In summary, Aveo Pharmaceuticals Inc. is a versatile company in the oncology space, focused on drug development, commercialization, and significant collaborations to enhance treatment options for patients suffering from cancer. Their portfolio continues to evolve as new therapies are developed and existing ones are optimized within their pipeline.
Segments
1. Oncology Drug Development: Aveo specializes in the development of novel therapeutics targeting various cancers. Their pipeline includes both early and late-stage candidates, focusing on specific molecular targets and pathways that are critical in tumorigenesis and cancer progression.
2. Commercialization: In addition to drug development, Aveo has a commercial aspect that involves bringing their therapies to market once they receive regulatory approval. This includes marketing strategies, sales force deployment, and patient support programs.
3. Collaborative Partnerships: Aveo often collaborates with larger pharmaceutical companies and research institutions to enhance drug development processes, expand clinical trial capabilities, and access broader markets. These partnerships may focus on co-developing therapies or co-promoting products.
Products
1. Tivdak (tisotumab vedotin): This product is a monoclonal antibody-drug conjugate developed for the treatment of certain types of cancer, particularly cervical cancer. It’s designed to target tumor cells specifically, reducing the harmful effects on healthy tissue.
2. AV-203: A monoclonal antibody targeting the epidermal growth factor receptor (EGFR), which is involved in many cancers. AV-203 is still in the development stage and has shown promise in preclinical studies.
3. AV-101: This investigational compound targets a pathway that could influence cancer cell survival and proliferation. It is currently being evaluated in clinical trials for its efficacy and safety in treating various malignancies.
4. Customized Therapies: Aveo is also exploring the avenue of personalized medicine, which involves tailoring treatments based on the genetic makeup of both the patient and the tumor. This segment holds a lot of potential for the future of oncology.
Services
1. Clinical Trials Support: Aveo offers extensive support for clinical trial design, implementation, and management. They conduct phase I, II, and III trials to assess the safety and efficacy of their drug candidates.
2. Patient Assistance Programs: To enhance patient access to their therapies, Aveo provides patient support programs that help with medication access, treatment options, and support throughout the treatment journey.
3. Scientific Research and Development Services: The company often engages in R&D collaborations, providing expertise in drug discovery, development, and regulatory pathways to support innovative oncology therapies.
4. Regulatory Consulting: Aveo navigates the complex regulatory landscape to secure approvals from health authorities like the FDA. They provide consultancy services on submissions and compliance, ensuring that products meet necessary guidelines.
5. Educational Initiatives: Aveo is involved in educating healthcare professionals and patients about cancer treatment options, the importance of clinical trials, and the potential benefits of their therapies.
In summary, Aveo Pharmaceuticals Inc. is a versatile company in the oncology space, focused on drug development, commercialization, and significant collaborations to enhance treatment options for patients suffering from cancer. Their portfolio continues to evolve as new therapies are developed and existing ones are optimized within their pipeline.